Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced that CEO Sergio Traversa will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:40 a.m. ET. A live webcast will be available on the investor section of the company's website, with a replay accessible for 90 days post-event.
Relmada focuses on central nervous system diseases, particularly major depressive disorder, and is advancing its lead program, REL-1017, into late-stage development.
- Participation in a notable healthcare conference may enhance visibility and investor interest.
- REL-1017's advancement into late-stage development highlights the company's commitment to addressing major depressive disorder.
- None.
NEW YORK, March 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 10:40 a.m. Eastern Time.
A live webcast of the fireside chat will be available via the investor section of the Company's website and at https://wsw.com/webcast/oppenheimer9/rlmd/2720795. The webcast will be available for replay for 90 days following the event.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
tim@lifesciadvisors.com
Media Inquiries:
FischTank PR
relmada@fischtankpr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-participation-in-the-oppenheimer-31st-annual-healthcare-conference-301245549.html
SOURCE Relmada Therapeutics, Inc.
FAQ
When is Relmada Therapeutics participating in the Oppenheimer Conference?
What is the aim of Relmada Therapeutics' lead program REL-1017?
How can I access the webcast of the Relmada Therapeutics conference?
Is REL-1017 in late-stage development?
What is the focus area of Relmada Therapeutics?
